Delivers on its commitment to turn around its
Plant Protein business
Maple Leaf records consolidated year over year
sales and Adjusted EBITDA growth in 2023
TSX: MFI
www.mapleleaffoods.com
MISSISSAUGA, ON, Feb. 22,
2024 /PRNewswire/ - Maple Leaf Foods Inc. ("Maple
Leaf Foods" or "the Company") (TSX: MFI) today reported its
financial results for the fourth quarter and full year ended
December 31, 2023.
"In 2023 we made great progress in advancing our strategic
Blueprint, delivering top-line growth of 2.7%, recording an
increase of $155 million in Adjusted
EBITDA to $428 million for the year,
and meeting our commitment to achieve Adjusted EBITDA neutral or
better in our Plant Protein business as we exited the year," said
Curtis Frank, President and Chief
Executive Officer of Maple Leaf Foods. "While these are important
achievements, and we are pleased with our relative performance in
challenging market conditions, we acknowledge that we still have
work to do to realize our full potential."
"In the fourth quarter, our Meat Protein results fell below our
expectations, as a result of global pork market dislocations that
have persisted longer and deeper than we anticipated, and a
challenging consumer demand environment, plus we still have a short
distance to go to bring home the full benefits from our London
Poultry and Bacon Centre of Excellence projects," continued Frank.
"With our refreshed strategic Blueprint announced today, we are
sharpening our execution focus, bringing together our Meat Protein
and Plant Protein businesses to build a powerful platform from
which to grow in the U.S. market, and aligning the talents of our
team to leverage the strength of our portfolio of leading brands,
leadership in sustainability and world-class assets."
Fourth Quarter 2023 Highlights
- Total Company sales growth of 0.6% to $1,192.7 million, with an Adjusted Earnings
Before Interest, Taxes, Depreciation and Amortization
("EBITDA")(i) margin of 10.1%.
- Meat Protein Group sales grew to $1,159.0 million, an increase of 0.8% year over
year. Adjusted EBITDA was $122.0
million, Adjusted EBITDA margin was 10.5%, an improvement of
390 basis points from the fourth quarter of 2022.
- London Poultry plant and Bacon Centre of Excellence delivered
approximately $25 million incremental
Adjusted EBITDA.
- Plant Protein Group sales were $36.5
million. Plant Protein Group Adjusted EBITDA improved by
$20.5 million year over year to a
gain of $0.1 million, achieving the
Company's Adjusted EBITDA target of neutral or better in the latter
half of 2023.
- Capital expenditures were $40.8
million.
2023 Highlights
- Total Company sales grew by 2.7% to $4,867.9 million, with an Adjusted EBITDA margin
of 8.8%.
- Meat Protein Group sales grew to $4,736.2 million, an increase of 3.1%. Adjusted
EBITDA was $463.0 million and
Adjusted EBITDA Margin was 9.8%.
- Plant Protein Group Sales were $147.0
million. Plant Protein Group Adjusted EBITDA improved by
68.8% to a loss of $32.9
million.
- Capital expenditures of $196.6
million.
- The Company had Net Debt(i) of $1,747.5 million and undrawn committed credit of
$447.2 million as at year end, and is
focused on deleveraging the Balance Sheet.
(i)
Refer to the section titled Non-IFRS Financial Measures in this
news release.
|
Financial Highlights
|
|
|
|
|
|
|
As at or for
the
|
Measure(i)
(Unaudited)
|
Three months ended
December 31,
|
Twelve months
ended December 31,
|
|
2023
|
|
2022
|
|
Change
|
|
2023
|
|
2022
|
|
Change
|
Sales
|
|
$
1,192.7
|
|
$
1,185.5
|
|
0.6 %
|
|
$
4,867.9
|
|
$
4,739.1
|
|
2.7 %
|
Net (Loss)
|
|
$
(9.3)
|
|
$
(41.5)
|
|
77.5 %
|
|
$
(125.0)
|
|
$ (311.9)
|
|
59.9 %
|
Basic Loss per
Share
|
|
$
(0.08)
|
|
$
(0.34)
|
|
76.5 %
|
|
$
(1.03)
|
|
$
(2.52)
|
|
59.1 %
|
Adjusted Operating
Earnings(ii)
|
|
$
57.5
|
|
$
1.8
|
|
nm(iii)
|
|
$
193.2
|
|
$
65.7
|
|
194.0 %
|
Adjusted (Loss)
Earnings per Share(ii)
|
|
$
0.08
|
|
$
(0.28)
|
|
nm(iii)
|
|
$
0.09
|
|
$
(0.26)
|
|
nm(iii)
|
Adjusted EBITDA - Meat
Protein Group(ii)
|
|
$
122.0
|
|
$
76.1
|
|
60.3 %
|
|
$
463.0
|
|
$
378.7
|
|
22.3 %
|
Adjusted EBITDA - Plant
Protein Group(ii)
|
|
$
0.1
|
|
$
(20.4)
|
|
nm(iii)
|
|
$
(32.9)
|
|
$ (105.4)
|
|
68.8 %
|
Free Cash
Flow(ii)
|
|
$
63.4
|
|
$
20.7
|
|
206.3 %
|
|
$
89.0
|
|
$
(20.9)
|
|
nm(iii)
|
Construction
Capital(ii)
|
|
|
|
|
|
|
|
$
—
|
|
$
9.6
|
|
nm(iii)
|
Net
Debt(ii)
|
|
|
|
|
|
|
|
$
(1,747.5)
|
|
$
(1,619.3)
|
|
7.9 %
|
Adjusted EBT(ii)
|
|
$
16.4
|
|
$
(21.8)
|
|
nm(iii)
|
|
$
34.2
|
|
$
4.4
|
|
677.3 %
|
(i)
All financial measures in millions of dollars except Basic and
Adjusted Earnings per Share.
|
(ii)
Refer to the section titled Non-IFRS Financial Measures in this
news release.
|
(iii)
Not meaningful.
|
Fourth Quarter 2023
Sales for the fourth quarter increased 0.6% to $1,192.7 million compared to $1,185.5 million last year. Sales growth in the
Meat Protein Group was partly offset by an 8.9% sales decline in
the Plant Protein Group. For more details on sales performance by
operating segment, please refer to the Operating Review.
Net loss for the fourth quarter of 2023 was $9.3 million ($0.08
loss per basic share) compared to net loss of $41.5 million ($0.34 loss per basic share) last year. The
improvement in performance for the quarter was driven by pricing to
mitigate inflation, stronger pork markets, benefits from strategic
construction projects, and the non-repeated estimated impact of
$23 million from the cybersecurity
incident in 2022 combined with achieving the goal of Adjusted
EBITDA neutral performance in the Plant Protein segment. This was
partially offset by higher input costs and increased interest
expense. Net loss for the fourth quarter of 2023 also included
start-up expenses of $29.7 million
(2022: $25.8 million) associated with
Construction Capital projects, and lower gains on biological
assets mark to market adjustments, both of which are excluded from
the calculation of Adjusted Operating Earnings.
Adjusted Operating Earnings for the fourth quarter of 2023
were $57.5 million compared to
$1.8 million last year, consistent
with the factors noted above.
Adjusted EBITDA Margin for the fourth quarter increased to
10.1% from 4.7% last year, consistent with the factors noted
above.
Adjusted Earnings Before Taxes ("Adjusted EBT") for the fourth
quarter of 2023 were $16.4 million
compared to a loss of $21.7 million
last year, consistent with the factors noted above.
Basic Earnings per Share was a loss of $0.08 for the fourth
quarter of 2023 compared to a loss of $0.34 last year, consistent with the factors
described above.
Adjusted Earnings per Share in the fourth quarter of 2023
was $0.08 compared to a loss of
$0.28 last year.
Full Year 2023
Sales for 2023 were $4,867.9
million compared to $4,739.1
million last year, an increase of 2.7%. Sales growth in the
Meat Protein Group was partly offset by a decline in the Plant
Protein Group. For more details on sales performance by operating
segment, please refer to the Operating Review.
Net loss for 2023 was $125.0
million ($1.03 loss per basic
share) compared to a net loss of $311.9
million ($2.52 loss per basic
share) last year. In the Meat Protein Group stronger commercial
performance more than offset market headwinds and inflation. In the
Plant Protein Group improved operational performance more than
offset lower volumes. In the prior year, the Plant Protein Group
also included a $190.9 million
one-time impairment charge. Interest expense increased by
$94.8 million, reflecting the net
debt levels associated with Construction Capital projects and
increases in borrowing rates. Net loss for the year also included
start-up expenses of $122.3 million
(2022: $59.3 million) associated with
Construction Capital projects, as well as net losses from non-cash
fair value changes in biological assets and derivative contracts of
$24.6 million (2022: $14.0 million), all of which are excluded in the
calculation of Adjusted Operating Earnings.
Adjusted Operating Earnings for 2023 were $193.2 million compared to $65.7 million last year, and Adjusted Earnings
per Share for 2023 was $0.09 compared
to loss of $0.26 last year.
Adjusted Earnings Before Taxes ("Adjusted EBT") for 2023
were $34.2 million compared to
$4.4 million last year due to similar
factors as noted above.
For further discussion on key metrics and a discussion of
results by operating segment, refer to the section titled Operating
Review.
Note: Several items
are excluded from the discussions of underlying earnings
performance as they are not representative of ongoing operational
activities. Refer to the section entitled Non-IFRS Financial
Measures at the end of this news release for a description and
reconciliation of all non-IFRS financial measures.
|
Operating Review
During the year ended December 31, 2023, the Company
had two reportable segments. These segments offer different
products, with separate organizational structures, brands, and
financial and marketing strategies. The Company's Chief Operating
Decision Makers regularly review internal reports for these
businesses. Performance of the Meat Protein Group is based on
profitable revenue growth, Adjusted Operating Earnings, Adjusted
EBITDA, while the performance of the Plant Protein Group in the
short term is focused on obtaining Adjusted EBITDA neutral results.
Fourth Quarter 2023
The following table summarizes the Company's sales, gross
profit, SG&A expenses, Adjusted Operating Earnings, Adjusted
EBITDA, Adjusted EBITDA Margin and Adjusted EBT by operating
segment for the fourth quarters ended December 31, 2023
and December 31, 2022:
|
Three months ended
December 31, 2023
|
Three months ended
December 31, 2022
|
($
millions)(i)
(Unaudited)
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Sales
|
$
1,159.0
|
36.5
|
(2.8)
|
$
1,192.7
|
$
1,149.6
|
40.0
|
(4.1)
|
$
1,185.5
|
Gross profit
(loss)
|
$
124.0
|
5.1
|
6.4
|
$
135.5
|
$
82.2
|
(10.3)
|
28.7
|
$ 100.6
|
Selling, General and
Administrative
expenses
|
$
91.3
|
9.9
|
—
|
$
101.3
|
$
80.0
|
15.8
|
—
|
$
95.9
|
Adjusted Operating
(Loss) Earnings(iii)
|
$
62.3
|
(4.8)
|
—
|
$
57.5
|
$
28.0
|
(26.2)
|
—
|
$
1.8
|
Adjusted
EBITDA(iii)
|
$
122.0
|
0.1
|
(1.9)
|
$
120.2
|
$
76.1
|
(20.4)
|
(0.5)
|
$
55.3
|
Adjusted EBITDA
Margin(iii)
|
10.5 %
|
0.3 %
|
n/a
|
10.1 %
|
6.6 %
|
(51.0) %
|
n/a
|
4.7 %
|
Adjusted
EBT(iii)
|
$
23.2
|
(5.0)
|
(1.9)
|
$
16.4
|
$
6.7
|
(28.0)
|
(0.5)
|
$ (21.7)
|
(i)
|
Totals may not add
due to rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, changes in the fair value of biological assets and
derivatives, and non-allocated costs which are comprised of
expenses not separately identifiable to reportable segments or are
not part of the measures used by the Company when assessing a
segment's operating results.
|
(iii)
|
Refer to the section
titled Non-IFRS Financial Measures in this news
release.
|
Meat Protein Group
The Meat Protein Group is comprised of prepared meats,
ready-to-cook and ready-to-serve meals, snack kits, value-added
fresh pork and poultry products that are sold to retail,
foodservice and industrial channels, and agricultural operations in
pork and poultry. The Meat Protein Group includes leading brands
such as Maple Leaf®, Maple Leaf Prime®, Maple Leaf Natural
Selections®, Schneiders®, Schneiders® Country Naturals®, Mina®,
Greenfield Natural Meat Co.®, and other leading regional
brands.
Sales for the fourth quarter increased 0.8% to $1,159.0 million compared to $1,149.6 million last year. Sales growth was
driven by volume growth, pricing action implemented in prior
quarters to mitigate the impact of inflation, and favourable mix
shift. Prior year sales volumes were also impacted by the
cybersecurity incident.
Gross profit for the fourth quarter of 2023 was $124.0 million (gross margin of 10.7%) compared
to $82.2 million (gross margin of
7.2%) last year. Gross profit was positively impacted by pricing
action to catch up to inflation, improved pork market conditions,
and benefits from strategic capital, partially offset by cost
inflation, unfavourable product mix, and start up expenses. Prior
year results were impacted by the cybersecurity incident. Gross
profit for the fourth quarter of 2023 included start-up expenses of
$29.7 million (2022: $25.8 million) associated with Construction
Capital projects which are excluded from the calculation of
Adjusted Operating Earnings.
SG&A expenses for the fourth quarter of 2023 were
$91.3 million an increase from
$80.0 million last year. The increase
was due to inflationary pressures on base compensation as well as
higher advertising and promotional spend.
Adjusted Operating Earnings for the fourth quarter of
2023 were $62.3 million compared
to $28.0 million last year, driven by
the factors noted above.
Adjusted EBITDA Margin for the fourth quarter was
10.5% compared to 6.6% last year, consistent with the factors
noted above as well as benefits from London poultry plant and Bacon Centre of
Excellence.
Adjusted EBT for the fourth quarter of 2023 were
$23.2 million compared to
$6.7 million last year, driven by
factors consistent with those noted above, as well as a
$20.3 million increase in interest
expense as a result of increased interest rates and higher debt,
and increased depreciation expense all related to continued capital
investment.
Plant Protein Group
The Plant Protein Group is comprised of refrigerated plant
protein products, premium grain-based protein, and vegan cheese
products sold to retail, foodservice and industrial channels. The
Plant Protein Group includes the leading brands Lightlife® and
Field Roast™.
Sales for the fourth quarter were $36.5 million compared to $40.0 million last year, representing a decline
of 8.9%, or 9.1% excluding the impact of foreign exchange. Sales
decline was driven by lower retail volumes, partially offset by
pricing action implemented in prior quarters to mitigate
inflation.
Gross profit for the fourth quarter of 2023 was $5.1 million (gross margin of 13.9%)
compared to a loss of $10.3 million
(gross margin loss of 25.8%) last year. The improvement in gross
profit was driven by operational improvements, higher pricing,
partially offset by lower volumes.
SG&A expenses for the fourth quarter of 2023 were
$9.9 million (27.2% of sales),
compared to $15.8 million (39.5% of
sales) last year. The decrease in SG&A expenses was primarily
attributable to lower advertising and promotional expenses and
lower people costs as a result of restructuring in prior
quarters.
Adjusted Operating Earnings for the fourth quarter of
2023 were a loss of $4.8 million
compared to a loss of $26.2 million
last year. The improvement in Adjusted Operating Earnings is
consistent with the factors noted above.
Adjusted EBITDA for the fourth quarter of 2023 was $0.1 million compared to a loss of $20.4 million last year, consistent with the
factors noted above.
Full Year 2023
The following table summarizes the Company's sales, gross
profit, SG&A expenses, Adjusted Operating Earnings, Adjusted
EBITDA, Adjusted EBITDA Margin and Adjusted EBT by operating
segment for the years ended December 31, 2023 and
December 31, 2022.
|
2023
|
2022
|
($
millions)(i)
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Sales
|
$
4,736.2
|
147.0
|
(15.3)
|
$
4,867.9
|
$
4,593.6
|
169.3
|
(23.9)
|
$
4,739.1
|
Gross profit
(loss)
|
$
478.2
|
(2.2)
|
(24.6)
|
$
451.4
|
$ 474.7
|
(36.5)
|
(14.0)
|
$ 424.1
|
Selling, General and
Administrative
expenses
|
$
355.4
|
49.7
|
—
|
$
405.1
|
$ 338.9
|
92.8
|
—
|
$ 431.7
|
Adjusted Operating
(Loss) Earnings(iii)
|
$
245.2
|
(51.9)
|
—
|
$
193.2
|
$ 190.3
|
(124.5)
|
—
|
$
65.7
|
Adjusted
EBITDA(iii)
|
$
463.0
|
(32.9)
|
(2.5)
|
$
427.6
|
$ 378.7
|
(105.4)
|
(0.5)
|
$ 272.9
|
Adjusted EBITDA
Margin(iii)
|
9.8 %
|
(22.4) %
|
n/a
|
8.8 %
|
8.2 %
|
(62.2) %
|
n/a
|
5.8 %
|
Adjusted
EBT(iii)
|
$
89.5
|
(52.8)
|
(2.5)
|
$
34.2
|
$ 139.0
|
(134.1)
|
(0.5)
|
$
4.4
|
(i)
|
Totals may not add
due to rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, changes in the fair value of biological assets and
derivatives, and non-allocated costs which are comprised of
expenses not separately identifiable to reportable segments or are
not part of the measures used by the Company when assessing a
segment's operating results.
|
(iii)
|
Refer to the section
titled Non-IFRS Financial Measures in this news
release.
|
Meat Protein Group
Sales for 2023 increased 3.1% to $4,736.2 million compared to $4,593.6 million last year. Sales growth was
driven by pricing actions implemented to reflect higher input
costs, favourable sales mix and foreign exchange. These positive
factors were partially offset by commodity market headwinds and
lower sales volumes.
Gross profit for 2023 was largely flat year over year at
$478.2 million (gross margin of
10.1%) compared to $474.7 million
(gross margin of 10.3%) last year as pricing actions were offset
largely by higher input costs, market headwinds and start up
expenses. Gross profit for 2023 included start-up expenses of$122.3
million (2022: $54.5 million)
associated with Construction Capital projects, which are
excluded in the calculation of Adjusted Operating Earnings.
SG&A expenses for 2023 were $355.4 million compared to $338.9 million last year. The increase in
SG&A expenses was driven by inflationary pressures on base
compensation and discretionary spending, partially offset by lower
variable compensation.
Adjusted Operating Earnings for 2023 were $245.2 million compared to $190.3 million last year, driven by factors
noted above.
Adjusted EBITDA for 2023 were $463.0
million compared to $378.7
million last year, driven by factors consistent with those
noted above, in addition to increased depreciation expenses added
back as a result of significant capital expansion largely in
London. Adjusted EBITDA Margin for
2023 was 9.8% compared to 8.2% last year, also driven by factors
consistent with those noted above.
Adjusted EBT for 2023 were $89.5
million compared to $139.0
million last year, driven by factors consistent with those
noted above, as well as a $104.3
million increase in interest expense as a result of
increased interest rates and higher debt related to continued
capital investment.
Plant Protein Group
Sales for 2023 were $147.0 million
compared to $169.3 million last year,
representing a decrease of 13.2%, or 16.3% after excluding the
impact of foreign exchange. The sales decline was driven by lower
volumes in retail and foodservice products, partially offset by
pricing action implemented in prior quarters to mitigate
inflation.
Gross profit for 2023 was a loss of $2.2
million (gross margin loss of 1.5%) compared to a gross loss
of $36.5 million (gross margin loss
of 21.6%) last year. The improvement in gross profit was driven by
operational improvements, higher pricing to offset inflation, and
reduction in start-up expenses, partially offset by lower volumes.
Gross profit for 2023 included start-up expenses of nil (2022:
$4.8 million) associated with
Construction Capital projects which are excluded in the calculation
of Adjusted Operating Earnings.
SG&A expenses for 2023 were $49.7 million (33.8% of sales) compared to
$92.8 million (54.8% of sales) last
year. The decrease in SG&A expenses was driven by lower
advertising and promotional expense, lower people costs and lower
consulting costs.
Adjusted Operating Earnings for 2023 were a loss of
$51.9 million compared to a loss of
$124.5 million last year. This
improvement is consistent with the factors noted above.
Adjusted EBITDA for 2023 was a loss of $32.9 million compared to a loss of $105.4 million last year. This improvement is
consistent with the factors noted above.
Other Matters
On February 21, 2024, the Board of
Directors approved a quarterly dividend of $0.22 per share (an increase of $0.01 per share from the 2023 fourth quarter
dividends), $0.88 per share on an
annual basis, payable March 28, 2024
to shareholders of record at the close of business March 8, 2024. Unless indicated otherwise by the
Company at or before the time the dividend is paid, the dividend
will be considered an eligible dividend for the purposes of the
"Enhanced Dividend Tax Credit System". The Board of Directors has
also approved the issuance of common shares from treasury at a two
percent discount under the Company's Dividend Reinvestment Plan
("DRIP"). Under the DRIP, investors holding the Company's common
shares can receive common shares instead of cash dividend payments.
Further details, including how to enroll in the program are
available at
https://www.mapleleaffoods.com/investors/stock-information.com.
Conference Call
A conference call will be held at 8:00 a.m. ET on
February 22, 2024, to review Maple Leaf Foods' fourth quarter
financial results. To participate in the call, please dial
416-764-8650 or 1-888-664-6383. For those unable to participate,
playback will be made available an hour after the event at
416-764-8677 or 1-888-390-0541 (Passcode: 225124 #).
A webcast of the fourth quarter conference call will also be
available at: https://www.mapleleaffoods.com.
The Company's full consolidated financial statements
("Consolidated Financial Statements") and related Management's
Discussion and Analysis are available on the Company's website.
An investor presentation related to the Company's fourth quarter
financial results is available at www.mapleleaffoods.com and can be
found under Presentations and Webcasts on the Investors page.
Outlook
Maple Leaf Foods is a leading consumer protein company built on
a powerful portfolio of brands, with a leading voice in
sustainability and food security. The Company's strategic blueprint
defines how it will advance its vision to be the most sustainable
protein company on Earth while delivering on its commercial and
financial objectives.
The Company recognizes that macro-economic challenges and global
conflict continue to define the post-pandemic environment. This is
resulting in higher interest rates, inflation, supply chain
tensions, and pressures on agricultural, commodity and foreign
exchange markets. As a result, consumers and business alike are
adapting their behaviours which contributes to shifts in demand and
product mix. The Company leverages its data-driven insights to stay
close to these dynamics, and it is confident in the resilience of
its brands, business model and strategy to manage through these
transitory conditions.
In the near term, the Company is realigning its organizational
structure to align with the refresh of its strategic blueprint by
bringing together its Meat and Plant Protein businesses. This shift
supports a clear and consistent focus on driving profitable growth
in Canada, the U.S. and
internationally across its entire protein and prepared foods
portfolio.
For the full year 2024, the Company expects:
- Low-to mid-single digit revenue growth
- Adjusted EBITDA margin expansion from 2023, supported by the
benefits of:
- The profitable growth of its leading portfolio of Meat and
Plant Protein brands
- Returns from investments in the London Poultry Plant and the
Bacon Centre of Excellence
- Leadership in Sustainable Meats
- Driving operational and cost efficiency
- Profitable growth in the Plant Protein category, having
achieved the target of Adjusted EBITDA neutral exiting 2023
- To achieve its Meat Protein target of 14% to 16% Adjusted
EBITDA Margin when markets normalize
- To generate strong free cash flow and delever its balance sheet
by:
- Improving profitability
- Generating the targeted returns on its capital investments at
the London Poultry Plant and the Bacon Centre of Excellence,
including reducing start-up expenses, maximizing efficiencies and
onboarding new customers
- Exercising disciplined capital management, with total capital
expenditures this year expected to be in a more typical range of
$170 - $190
million largely focused on maintenance capital and
optimization of its existing network
Maple Leaf Foods will also continue to advance its ambitious
sustainability agenda, including leading the real food movement,
advancing its animal care initiatives, seeking solutions to address
food insecurity, accelerating its efforts to reduce its
environmental footprint and continuing to deliver safe food made in
a safe work environment.
Non-IFRS Financial Measures
The Company uses the following non-IFRS measures: Adjusted
Operating Earnings, Adjusted Earnings per Share, Adjusted EBITDA,
Adjusted EBITDA Margin, Adjusted EBT, Construction Capital, Net
Debt, Free Cash Flow and Return on Net Assets. Management believes
that these non-IFRS measures provide useful information to
investors in measuring the financial performance of the Company for
the reasons outlined below. These measures do not have a
standardized meaning prescribed by IFRS and therefore they may not
be comparable to similarly titled measures presented by other
publicly traded companies and should not be construed as an
alternative to other financial measures determined in accordance
with IFRS.
Adjusted Operating Earnings, Adjusted EBITDA, Adjusted EBITDA
Margin and Adjusted EBT
Adjusted Operating Earnings, Adjusted EBITDA and Adjusted EBITDA
Margin are non-IFRS measures used by Management to evaluate
financial operating results. Adjusted Operating Earnings is defined
as earnings before income taxes adjusted for items that are not
considered representative of ongoing operational activities of the
business and certain items where the economic impact of the
transactions will be reflected in earnings in future periods when
the underlying asset is sold or transferred. Adjusted EBITDA is
defined as Adjusted Operating Earnings plus depreciation and
intangible asset amortization, adjusted for items included in other
expense that are considered representative of ongoing operational
activities of the business. Adjusted EBITDA Margin is calculated as
Adjusted EBITDA divided by sales. Adjusted EBT is used annually by
the Company to evaluate its performance and is a component of
calculating bonus entitlements under the Company's short term
incentive plan. It is defined as Adjusted EBITDA, less depreciation
and amortization, and interest expense. Interest expense is
allocated to the operating segments for this metric on a legal
entity basis.
The tables below provide a reconciliation of earnings (loss)
before income taxes as reported under IFRS in the Consolidated
Financial Statements to Adjusted Operating Earnings, Adjusted
EBITDA and Adjusted EBT for the three and twelve months ended
December 31, as indicated below.
Management believes that these non-IFRS measures are useful in
assessing the performance of the Company's ongoing operations and
its ability to generate cash flows to fund its cash requirements,
including the Company's capital investment program.
|
Three months ended
December 31, 2023
|
Three months ended
December 31, 2022
|
($
millions)(i) (Unaudited)
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
(Loss) earnings
before income taxes
|
$
32.8
|
(4.8)
|
(36.7)
|
$ (8.7)
|
$ (0.4)
|
(29.4)
|
0.2
|
$
(29.6)
|
Interest expense and
other financing costs
|
—
|
—
|
41.2
|
41.2
|
—
|
—
|
23.0
|
23.0
|
Other expense
(income)
|
(1.0)
|
0.1
|
1.8
|
0.9
|
0.5
|
(0.4)
|
5.5
|
5.5
|
Restructuring and other
related costs
|
0.9
|
(0.1)
|
—
|
0.8
|
2.1
|
3.6
|
—
|
5.7
|
Earnings (loss) from
operations
|
$
32.7
|
(4.8)
|
6.4
|
$
34.2
|
$
2.2
|
(26.2)
|
28.7
|
$
4.7
|
Start-up expenses from
Construction Capital(iii)
|
29.7
|
—
|
—
|
29.7
|
25.8
|
—
|
—
|
25.8
|
Change in fair value of
biological assets
|
—
|
—
|
(8.9)
|
(8.9)
|
—
|
—
|
(27.0)
|
(27.0)
|
Unrealized (gain) loss
on derivative contracts
|
—
|
—
|
2.5
|
2.5
|
—
|
—
|
(1.7)
|
(1.7)
|
Adjusted Operating
Earnings
|
$
62.3
|
(4.8)
|
—
|
$
57.5
|
$ 28.0
|
(26.2)
|
—
|
$
1.8
|
Depreciation and
amortization
|
58.6
|
5.0
|
—
|
63.6
|
48.6
|
5.4
|
—
|
54.0
|
Items included in other
income (expense)
representative of ongoing
operations(iv)
|
1.0
|
(0.1)
|
(1.9)
|
(0.9)
|
(0.5)
|
0.4
|
(0.5)
|
(0.6)
|
Adjusted
EBITDA
|
$
122.0
|
0.1
|
(1.9)
|
$
120.2
|
$ 76.1
|
(20.4)
|
(0.5)
|
$ 55.3
|
Adjusted EBITDA
Margin
|
10.5 %
|
0.3 %
|
n/a
|
10.1 %
|
6.6 %
|
(51.0) %
|
n/a
|
4.7 %
|
Interest expense and
other financing costs
|
(41.2)
|
(0.1)
|
—
|
(41.2)
|
(20.9)
|
(2.2)
|
—
|
(23.0)
|
Interest
income
|
1.1
|
—
|
—
|
1.1
|
—
|
—
|
—
|
—
|
Depreciation and
amortization
|
(58.6)
|
(5.0)
|
—
|
(63.6)
|
(48.6)
|
(5.4)
|
—
|
(54.0)
|
Adjusted
EBT
|
$
23.2
|
(5.0)
|
(1.9)
|
$
16.4
|
$
6.7
|
(28.0)
|
(0.5)
|
$
(21.7)
|
(i)
|
Totals may not add
due to rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, and non-allocated costs which are comprised of income
and expenses not separately identifiable to reportable segments or
are not part of the measures used by the Company when assessing a
segment's operating results.
|
(iii)
|
Start-up expenses
are temporary costs as a result of operating new facilities that
are or have been classified as Construction Capital. These costs
can include training, product testing, yield and labour efficiency
variances, duplicative overheads and other temporary expenses
required to ramp-up production.
|
(iv)
|
Primarily includes
certain costs associated with sustainability projects, gains and
losses on the impairment and sale of long-term assets, gains and
losses on investments, and other miscellaneous
expenses.
|
|
|
|
Twelve months
ended December 31, 2023
|
Twelve months ended
December 31, 2022
|
($
millions)(i)
(Unaudited)
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Earnings (loss)
before income taxes
|
$
105.3
|
(68.0)
|
(179.9)
|
$
(142.6)
|
$
123.2
|
(344.6)
|
(77.6)
|
$
(299.0)
|
Interest expense and
other financing costs
|
—
|
—
|
150.9
|
150.9
|
—
|
—
|
56.0
|
56.0
|
Impairment of
goodwill
|
—
|
—
|
—
|
—
|
—
|
190.9
|
—
|
190.9
|
Other
expense
|
9.2
|
0.7
|
4.5
|
14.4
|
5.0
|
1.8
|
7.5
|
14.4
|
Restructuring and other
related costs
|
8.3
|
15.4
|
—
|
23.7
|
7.5
|
22.6
|
—
|
30.1
|
Earnings (loss) from
operations
|
$
122.8
|
(51.9)
|
(24.6)
|
$
46.3
|
$
135.8
|
(129.3)
|
(14.0)
|
$ (7.6)
|
Start-up expenses from
Construction Capital(iii)
|
122.3
|
—
|
—
|
122.3
|
54.5
|
4.8
|
—
|
59.3
|
Change in fair value of
biological assets
|
—
|
—
|
19.6
|
19.6
|
—
|
—
|
15.1
|
15.1
|
Unrealized gain on
derivative contracts
|
—
|
—
|
5.0
|
5.0
|
—
|
—
|
(1.1)
|
(1.1)
|
Adjusted Operating
Earnings
|
$
245.2
|
(51.9)
|
—
|
$
193.2
|
$
190.3
|
(124.5)
|
—
|
$ 65.7
|
Depreciation and
amortization
|
227.0
|
19.7
|
—
|
246.7
|
193.5
|
18.9
|
—
|
212.4
|
Items included in other
income (expense)
representative of ongoing
operations(iv)
|
(9.2)
|
(0.7)
|
(2.5)
|
(12.4)
|
(5.0)
|
0.2
|
(0.5)
|
(5.3)
|
Adjusted
EBITDA
|
$
463.0
|
(32.9)
|
(2.5)
|
$
427.6
|
$
378.7
|
(105.4)
|
(0.5)
|
$
272.9
|
Adjusted EBITDA
Margin
|
9.8 %
|
(22.4 %)
|
n/a
|
8.8 %
|
8.2 %
|
(62.2 %)
|
n/a
|
5.8 %
|
Interest expense and
other financing costs
|
(150.6)
|
(0.2)
|
—
|
(150.9)
|
(46.3)
|
(9.8)
|
—
|
(56.0)
|
Interest
income
|
4.2
|
—
|
—
|
4.2
|
—
|
—
|
—
|
—
|
Depreciation and
amortization
|
(227.0)
|
(19.7)
|
—
|
(246.7)
|
(193.5)
|
(18.9)
|
—
|
(212.4)
|
Adjusted
EBT
|
$
89.5
|
(52.8)
|
(2.5)
|
$
34.2
|
$
139.0
|
(134.1)
|
(0.5)
|
$
4.4
|
(i)
|
Totals may not add
due to rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, and non-allocated costs which are comprised of income
and expenses not separately identifiable to reportable segments or
are not part of the measures used by the Company when assessing a
segment's operating results.
|
(iii)
|
Start-up expenses
are temporary costs as a result of operating new facilities that
are or have been classified as Construction Capital. These costs
can include training, product testing, yield and labour efficiency
variances, duplicative overheads and other temporary expenses
required to ramp-up production.
|
(iv)
|
Primarily includes
certain costs associated with sustainability projects, gains and
losses on the sale of long-term assets, legal settlements, and
other miscellaneous expenses.
|
Adjusted Earnings per Share
Adjusted Earnings per Share, a non-IFRS measure, is used by
Management to evaluate financial operating results. It is defined
as basic earnings per share and is adjusted on the same basis as
Adjusted Operating Earnings. The table below provides a
reconciliation of basic earnings per share as reported under
IFRS in the Consolidated Financial Statements to Adjusted Earnings
per Share for the years ended December
31, as indicated below. Management believes this basis is
the most appropriate on which to evaluate financial results as they
are representative of the ongoing operations of the
Company.
($ per
share)
(Unaudited)
|
Three months ended
December 31,
|
Twelve months
ended December 31,
|
2023
|
2022
|
2023
|
2022
|
Basic loss per
share
|
|
$
(0.08)
|
|
$
(0.34)
|
|
$
(1.03)
|
|
$
(2.52)
|
Impairment of
goodwill
|
|
—
|
|
—
|
|
—
|
|
1.54
|
Restructuring and other
related costs(i)
|
|
—
|
|
0.04
|
|
0.18
|
|
0.20
|
Items included in other
expense not considered
representative of ongoing
operations(ii)
|
|
0.01
|
|
0.03
|
|
0.04
|
|
0.06
|
Start-up expenses from
Construction Capital(iii)
|
|
0.18
|
|
0.16
|
|
0.75
|
|
0.36
|
Change in fair value of
biological assets
|
|
(0.05)
|
|
(0.16)
|
|
0.12
|
|
0.09
|
Change in unrealized
and deferred loss (gain) on
derivative contracts
|
|
0.02
|
|
(0.01)
|
|
0.03
|
|
(0.01)
|
Adjusted Earnings
per Share(iv)
|
|
$
0.08
|
|
$
(0.28)
|
|
$
0.09
|
|
$
(0.26)
|
(i)
|
Includes per share
impact of restructuring and other related costs, net of
tax.
|
(ii)
|
Primarily includes
legal fees and settlements, gains or losses on investment property,
and transaction related costs, net of tax.
|
(iii)
|
Start-up expenses
are temporary costs as a result of operating new facilities that
are or have been classified as Construction Capital. These costs
can include training, product testing, yield and labour efficiency
variances, duplicative overheads and other temporary expenses
required to ramp-up production, net of tax.
|
(iv)
|
Totals may not add
due to rounding.
|
Construction Capital
Construction Capital, a non-IFRS measure, is used by Management
to evaluate the amount of capital resources invested in specific
strategic development projects that are not yet operational. It is
defined as investments and related financing charges in projects
over $50.0 million that are related
to longer-term strategic initiatives, with no returns expected for
at least 12 months from commencement of construction and the asset
is re-categorized from Construction Capital once operational. There
are no Construction Capital projects as at December 31, 2023 as all projects have been
completed.
($
thousands)
|
|
2023
|
|
2022
|
Property and
equipment and intangibles at January 1
|
|
$
2,663,985
|
|
$
2,554,483
|
Other capital and
intangible assets at January 1(i)
|
|
2,654,419
|
|
1,811,164
|
Construction Capital
at January 1
|
|
$
9,566
|
|
$ 743,319
|
Additions
|
|
41,931
|
|
163,665
|
Transfers from
Construction Capital
|
|
(51,497)
|
|
(897,418)
|
Construction Capital
at December 31
|
|
$
—
|
|
$
9,566
|
Other capital and
intangible assets at December 31(i)
|
|
2,596,839
|
|
2,654,419
|
Property and
equipment and intangibles at December 31
|
|
$
2,596,839
|
|
$
2,663,985
|
|
|
|
|
|
Construction Capital
debt financing(ii)(iii)
|
|
$
—
|
|
$
9,461
|
(i)
|
Other capital and
intangible assets consists of property and equipment and
intangibles that do not meet the definition of Construction
Capital.
|
(ii)
|
Does not include
$1,091.0 million in capital that has been transferred out but is
still in the start-up stage (2022: $993.1 million).
|
(iii)
|
Assumed to be fully
funded by debt to the extent that the Company has Net Debt
outstanding. Construction Capital debt financing excludes interest
paid and capitalized.
|
Net Debt
The following table reconciles Net Debt to amounts reported
under IFRS in the Company's Consolidated Financial Statements and
calculates the Net Debt to Adjusted EBITDA ratio as at December 31, as indicated below. The Company
calculates Net Debt as cash and cash equivalents, less long-term
debt and bank indebtedness, and calculates Net Debt to Adjusted
EBITDA as the absolute value of Net Debt divided by Adjusted
EBITDA. Management believes these measures are useful in assessing
the amount of financial leverage employed.
|
|
As at December
31,
|
($
thousands)
|
|
2023
|
|
2022
|
Cash and cash
equivalents
|
|
$
203,363
|
|
$
91,076
|
Current portion of
long-term debt
|
|
$
(400,735)
|
|
$
(921)
|
Long-term
debt
|
|
(1,550,080)
|
|
(1,709,493)
|
Total
debt
|
|
$
(1,950,815)
|
|
$
(1,710,414)
|
Net
Debt
|
|
$
(1,747,452)
|
|
$
(1,619,338)
|
Adjusted
EBITDA
|
|
427,588
|
|
272,874
|
Net Debt to Adjusted
EBITDA
|
|
4.1
|
|
5.9
|
Free Cash Flow
Free Cash Flow, a non-IFRS measure, is used by Management to
evaluate cash flow after investing in the maintenance of the
Company's asset base. It is defined as cash provided by operations,
less Maintenance Capital(i) and associated
interest paid and capitalized. The following table calculates Free
Cash Flow for the periods indicated below:
($ thousands)
(Unaudited)
|
Three months ended
December 31,
|
|
Twelve months
ended December 31,
|
2023
|
2022
|
|
2023
|
|
2022
|
Cash provided by
operating activities
|
|
$
83,012
|
|
$
42,320
|
|
|
$
176,883
|
|
$
49,318
|
Maintenance
Capital(i)
|
|
(19,235)
|
|
(21,528)
|
|
|
(86,602)
|
|
(69,889)
|
Interest paid and
capitalized related to
Maintenance Capital
|
|
(377)
|
|
(88)
|
|
|
(1,267)
|
|
(323)
|
Free Cash
Flow
|
|
$
63,400
|
|
$
20,704
|
|
|
$
89,014
|
|
$
(20,894)
|
(i)
|
Maintenance Capital
is defined as non-discretionary investment required to maintain the
Company's existing operations and competitive position. Growth
Capital is defined as discretionary investment meant to create
stakeholder value through initiatives that for example, expand
margins, increase capacities or create further competitive
advantage. For the twelve months ended December 31, total capital
spending of $198.2 million (2022: $355.7 million) shown on the
Consolidated Statements of Cash Flows is made up of Maintenance
Capital of $86.6 million (2022: $69.9 million), and Growth Capital
of $111.6 million (2022: $285.8 million). For the three months
ended December 31, total capital spending of $41.8 million (2022:
$98.0 million) is made up of Maintenance Capital of $19.2 million
(2022: $21.5 million), and Growth Capital of $22.6 million (2022:
$76.4 million).
|
Return on Net Assets ("RONA")
RONA is calculated by dividing tax effected earnings from
operations (adjusted for items which are not considered
representative of the underlying operations of the business) by
average monthly net assets. Net assets are defined as total assets
(excluding cash and deferred tax assets) less non-interest bearing
liabilities (excluding deferred tax liabilities). Management
believes that RONA is an appropriate basis upon which to evaluate
long-term financial performance.
Forward-Looking Statements
This document contains, and the Company's oral and written
public communications often contain, "forward-looking information"
within the meaning of applicable securities law. These statements
are based on current expectations, estimates, projections, beliefs,
judgements and assumptions based on information available at the
time the applicable forward-looking statement was made and in light
of the Company's experience combined with its perception of
historical trends. Such statements include, but are not limited to,
statements with respect to objectives and goals, in addition to
statements with respect to beliefs, plans, targets, goals,
objectives, expectations, anticipations, estimates, and intentions.
Forward-looking statements are typically identified by words such
as "anticipate", "continue", "estimate", "expect", "may", "will",
"project", "should", "could", "would", "believe", "plan", "intend",
"design", "target", "undertake", "view", "indicate", "maintain",
"explore", "entail", "schedule", "objective", "strategy", "likely",
"potential", "outlook", "aim", "propose", "goal", and similar
expressions suggesting future events or future performance. These
statements are not guarantees of future performance and involve
assumptions, risks and uncertainties that are difficult to
predict.
By their nature, forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or events to differ materially from those
anticipated in such forward-looking statements. The Company
believes the expectations reflected in the forward-looking
statements are reasonable, but no assurance can be given that these
expectations will prove to be correct and such forward-looking
statements should not be unduly relied upon.
Specific forward-looking information in this document may
include, but is not limited to, statements with respect to:
- assumptions about the post-pandemic economic recovery,
including the implications of inflationary pressures on customer
and consumer behaviour, supply chains and competitive
dynamics;
- expected future cash flows and the sufficiency thereof, sources
of capital at attractive rates, future contractual obligations,
future financing options, renewal of credit facilities, compliance
with credit facility covenants, and availability of capital to fund
growth plans, operating obligations and dividends;
- future performance, including future financial objectives,
goals and targets, category growth analysis, expected capital spend
and expected SG&A expenditures, global pork market dynamics,
Japan export market margin
outlook, labour markets, inflationary pressures (including the
ability to price for inflation);
- potential for a recurrence of a cybersecurity incident on the
Company's systems, business and operations, as well as the ability
to mitigate the financial and operational impacts, the success of
remediation and recovery efforts, the implications of data
exfiltration, and other ongoing risks associated with
cybersecurity;
- the execution of the Company's business strategy, including the
development and expected timing of business initiatives, brand
expansion and repositioning, plant protein category investment and
performance, market access in China and Japan, capital allocation decisions (including
investment in share repurchases under the NCIB) and investment in
potential growth opportunities and the expected returns associated
therewith;
- the impact of international trade conditions and markets on the
Company's business, including access to markets, implications
associated with the spread of foreign animal disease (such as
African Swine Fever ("ASF")) and other animal diseases such as
Avian Influenza, as well as other social, economic and political
factors that affect trade, including global conflicts;
- competitive conditions and the Company's ability to position
itself competitively in the markets in which it competes;
- capital projects, including planning, construction, estimated
expenditures, schedules, approvals, expected capacity, in-service
dates and anticipated benefits of construction of new facilities
and expansions of existing facilities;
- the Company's dividend policy, including future levels and
sustainability of cash dividends, the tax treatment thereof and
future dividend payment dates;
- the impact of commodity prices and foreign exchange impacts on
the Company's operations and financial performance, including the
use and effectiveness of hedging instruments;
- operating risks, including the execution, monitoring and
continuous improvement of the Company's food safety programs,
animal health initiatives, cost reduction initiatives, and service
levels (including service level penalties);
- the implementation, cost and impact of environmental
sustainability initiatives, the ability of the Company to achieve
its sustainability objectives, changing climate and sustainability
laws and regulation, changes in customer and consumer expectations
related to sustainability matters, as well as the anticipated
future cost of remediating environmental liabilities;
- the adoption of new accounting standards and the impact of such
adoption on the financial position of the Company;
- expectations regarding pension plan performance, including
future pension plan assets, liabilities and contributions; and
- developments and implications of actual or potential legal
actions.
Various factors or assumptions are typically applied by the
Company in drawing conclusions or making the forecasts,
projections, predictions or estimations set out in the
forward-looking statements. These factors and assumptions are based
on information currently available to the Company, including
information obtained by the Company from third-party sources and
include but are not limited to the following:
- expectations regarding the adaptations in operations, supply
chain, customer and consumer behaviour, economic patterns
(including but not limited to global pork markets), foreign
exchange rates, international trade dynamics and access to capital,
including possible presence or absence of structural changes
associated with economic recovery since the pandemic;
- the competitive environment, associated market conditions and
market share metrics, category growth or contraction, the expected
behaviour of competitors and customers and trends in consumer
preferences;
- the success of the Company's business strategy and the
relationship between pricing, inflation, volume and sales of the
Company's products;
- prevailing commodity prices (especially in pork and feed
markets), interest rates, tax rates and exchange rates;
- potential impacts related to cybersecurity matters, including
security costs, the potential for a future incident, the risks
associated with data exfiltration, the availability of insurance,
the effectiveness of remediation and prevention activities, third
party activities, ongoing impacts, customer, consumer and supplier
responses and regulatory considerations;
- the economic condition of and the sociopolitical dynamics
between Canada, the U.S.,
Japan and China, and the ability of the Company to
access markets and source ingredients and other inputs in light of
global sociopolitical disruption, and the ongoing impact of global
conflicts on inflation, trade and markets;
- the spread of foreign animal disease (including ASF and Avian
Influenza), preparedness strategies to manage such spread, and
implications for all protein markets;
- the availability of and access to capital to fund future
capital requirements and ongoing operations;
- expectations regarding participation in and funding of the
Company's pension plans;
- the availability of insurance coverage to manage certain
liability exposures;
- the extent of future liabilities and recoveries related to
legal claims;
- prevailing regulatory, tax and environmental laws; and
- future operating costs and performance, including the Company's
ability to achieve operating efficiencies and maintain sales
volumes, turnover of inventories and turnover of accounts
receivable.
Readers are cautioned that these assumptions may prove to be
incorrect in whole or in part. The Company's actual results may
differ materially from those anticipated in any forward-looking
statements.
Factors that could cause actual results or outcomes to differ
materially from the results expressed, implied, or projected in the
forward-looking statements contained in this document include,
among other things, risks associated with the following:
- presence or absence of adaptations or structural changes
arising since the economic recovery from the pandemic which may
have implications for the operations and financial performance of
the Company, as well the ongoing implications for macro
socio-economic trends;
- macro economic trends, including inflation, consumer behaviour,
recessionary indicators, labour availability and labour market
dynamics and international trade trends (including global pork
markets);
- the results of the Company's execution of its business plans,
the degree to which benefits are realized or not, and the timing
associated realizing those benefits, including the implications on
cash flow;
- competition, market conditions, and the activities of
competitors and customers, including the expansion or contraction
of key categories, inflationary pressures, pork market dynamics and
Japan export margins;
- cybersecurity and maintenance and operation of the Company's
information systems, processes and data, recovery, restoration and
long term impacts of the cybersecurity event, the risk of future
cybersecurity events, actions of third parties, risks of data
exfiltration, effectiveness of business continuity planning and
execution, and availability of insurance;
- the health status of livestock, including the impact of
potential pandemics;
- international trade and access to markets and supplies, as well
as social, political and economic dynamics, including global
conflicts;
- operating performance, including manufacturing operating
levels, fill rates and penalties;
- availability of and access to capital, and compliance with
credit facility covenants;
- decision respecting the return of capital to shareholders;
- the execution of capital projects and investment maintenance
capital;
- food safety, consumer liability and product recalls;
- climate change, climate regulation and the Company's
sustainability performance;
- strategic risk management;
- acquisitions and divestitures;
- fluctuations in the debt and equity markets;
- fluctuations in interest rates and currency exchange
rates;
- pension assets and liabilities;
- cyclical nature of the cost and supply of hogs and the
competitive nature of the pork market generally;
- the effectiveness of commodity and interest rate hedging
strategies;
- impact of changes in the market value of the biological assets
and hedging instruments;
- the supply management system for poultry in Canada;
- availability of plant protein ingredients;
- intellectual property, including product innovation, product
development, brand strategy and trademark protection;
- consolidation of operations and focus on protein;
- the use of contract manufacturers;
- reputation;
- weather;
- compliance with government regulation and adapting to changes
in laws;
- actual and threatened legal claims;
- consumer trends and changes in consumer tastes and buying
patterns;
- environmental regulation and potential environmental
liabilities;
- consolidation in the retail environment;
- employment matters, including complying with employment laws
across multiple jurisdictions, the potential for work stoppages due
to non-renewal of collective agreements, recruiting and retaining
qualified personnel, reliance on key personnel and succession
planning;
- pricing of products;
- managing the Company's supply chain;
- changes in International Financial Reporting Standards and
other accounting standards that the Company is required to adhere
to for regulatory purposes; and
- other factors as set out under the heading "Risk Factors" in
the Company's Management Discussion and Analysis for the year ended
December 31, 2023.
The Company cautions readers that the foregoing list of factors
is not exhaustive.
Readers are further cautioned that some of the forward-looking
information, such as statements concerning future capital
expenditures, Adjusted EBITDA Margin expansion, and the Company's
ability to achieve its financial targets or projections may be
considered to be financial outlooks for purposes of applicable
securities legislation. These financial outlooks are presented to
evaluate potential future earnings and anticipated future uses of
cash flows and may not be appropriate for other purposes. Readers
should not assume these financial outlooks will be
achieved.
More information about risk factors can be found under the
heading "Risk Factors" in the Company's Annual Management's
Discussion and Analysis for the year ended December 31, 2023,
that is available on SEDAR+ at www.sedarplus.ca. The reader should
review such section in detail. Additional information concerning
the Company, including the Company's Annual Information Form, is
available on SEDAR+ at www.sedarplus.ca.
All forward-looking statements included herein speak only as of
the date hereof. Unless required by law, the Company does not
undertake any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. All forward-looking statements
contained herein are expressly qualified by this cautionary
statement.
About Maple Leaf Foods Inc.
Maple Leaf Foods is a carbon neutral(i)
company with a vision to be the most sustainable protein
company on earth, responsibly producing food products under leading
brands including Maple Leaf®, Maple Leaf Prime®, Maple Leaf Natural
Selections®, Schneiders®, Schneiders® Country Naturals®,
Mina®, Greenfield Natural Meat Co.®, Lightlife® and Field Roast™.
The Company employs approximately 13,500 people and does business
primarily in Canada, the U.S. and
Asia. The Company is headquartered
in Mississauga, Ontario and its
shares trade on the Toronto Stock Exchange (MFI).
(i)
|
See the Company's 2022 Integrated Report that is
available on the Maple Leaf Foods website at
https://www.mapleleaffoods.com/wp-content/uploads/sites/6/2023/06/MLF-2022-Integrated-Report_Final.pdf
|
|
|
Consolidated Balance Sheets
(In thousands of
Canadian dollars)
(Audited)
|
As at December
31,
2023
|
As at December
31,
2022(i)
|
As at January 1,
2022(i)
|
ASSETS
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
$
203,363
|
|
$
91,076
|
|
$
162,031
|
Accounts
receivable
|
|
183,798
|
|
167,611
|
|
167,082
|
Notes
receivable
|
|
33,220
|
|
48,556
|
|
33,294
|
Inventories
|
|
542,392
|
|
485,979
|
|
409,677
|
Biological
assets
|
|
114,917
|
|
144,169
|
|
138,209
|
Income and other taxes
recoverable
|
|
88,896
|
|
57,497
|
|
1,830
|
Prepaid expenses and
other assets
|
|
44,865
|
|
50,266
|
|
24,988
|
Assets held for
sale
|
|
—
|
|
604
|
|
—
|
Total current
assets
|
|
$
1,211,451
|
|
$ 1,045,758
|
|
$
937,111
|
Property and
equipment
|
|
2,251,710
|
|
2,303,424
|
|
2,189,165
|
Right-of-use
assets
|
|
154,610
|
|
159,199
|
|
161,662
|
Investments
|
|
15,749
|
|
23,712
|
|
22,326
|
Investment
property
|
|
57,144
|
|
5,289
|
|
5,289
|
Employee
benefits
|
|
26,785
|
|
12,531
|
|
—
|
Other long-term
assets
|
|
22,336
|
|
12,493
|
|
9,780
|
Deferred tax
asset
|
|
40,854
|
|
42,541
|
|
39,907
|
Goodwill
|
|
477,353
|
|
477,353
|
|
658,673
|
Intangible
assets
|
|
345,129
|
|
360,561
|
|
365,318
|
Total long-term
assets
|
|
$
3,391,670
|
|
$ 3,397,103
|
|
$
3,452,120
|
Total
assets
|
|
$
4,603,121
|
|
$ 4,442,861
|
|
$
4,389,231
|
LIABILITIES AND
EQUITY
|
|
|
|
|
|
|
Accounts payable and
accruals
|
|
$
548,444
|
|
$
485,114
|
|
$
526,189
|
Current portion of
provisions
|
|
9,846
|
|
42,589
|
|
842
|
Current portion of
long-term debt
|
|
400,735
|
|
921
|
|
5,176
|
Current portion of
lease obligations
|
|
38,031
|
|
38,321
|
|
31,375
|
Income taxes
payable
|
|
2,382
|
|
2,311
|
|
23,853
|
Other current
liabilities
|
|
32,974
|
|
64,684
|
|
81,265
|
Total current
liabilities
|
|
$
1,032,412
|
|
$
633,940
|
|
$
668,700
|
Long-term
debt
|
|
1,550,080
|
|
1,709,493
|
|
1,247,073
|
Lease
obligations
|
|
142,286
|
|
144,569
|
|
144,391
|
Employee
benefits
|
|
64,196
|
|
64,280
|
|
97,629
|
Provisions
|
|
2,041
|
|
3,799
|
|
44,650
|
Other long-term
liabilities
|
|
1,124
|
|
1,841
|
|
1,057
|
Deferred tax
liability
|
|
296,203
|
|
221,606
|
|
147,060
|
Total long-term
liabilities
|
|
$
2,055,930
|
|
$ 2,145,588
|
|
$
1,681,860
|
Total
liabilities
|
|
$
3,088,342
|
|
$ 2,779,528
|
|
$
2,350,560
|
Shareholders'
equity
|
|
|
|
|
|
|
Share
capital
|
|
$
873,477
|
|
$
850,086
|
|
$
847,016
|
Retained
earnings
|
|
597,429
|
|
809,616
|
|
1,212,244
|
Contributed
surplus
|
|
3,227
|
|
—
|
|
5,371
|
Accumulated other
comprehensive
income (loss)
|
|
47,829
|
|
29,547
|
|
286
|
Treasury
shares
|
|
(7,183)
|
|
(25,916)
|
|
(26,246)
|
Total shareholders'
equity
|
|
$
1,514,779
|
|
$ 1,663,333
|
|
$
2,038,671
|
Total liabilities
and equity
|
|
$
4,603,121
|
|
$ 4,442,861
|
|
$
4,389,231
|
(i)
Restated, refer to Note 4 of the Company's Audited
Consolidated Financial Statements.
|
Consolidated Statements of Net (Loss) Earnings
|
Three months ended
December 31,
|
Twelve months
ended December 31,
|
(In thousands of
Canadian dollars, except share amounts)
|
|
2023
|
|
2022
|
|
2023
|
|
2022
|
|
|
(Unaudited)
|
|
(Unaudited)
|
|
(Audited)
|
|
(Audited)
|
Sales
|
|
$
1,192,749
|
|
$
1,185,522
|
|
$
4,867,928
|
|
$
4,739,063
|
Cost of goods
sold
|
|
1,057,274
|
|
1,084,947
|
|
4,416,554
|
|
4,314,925
|
Gross profit
|
|
$
135,475
|
|
$
100,575
|
|
$
451,374
|
|
$
424,138
|
Selling, general and
administrative expenses
|
|
101,262
|
|
95,850
|
|
405,067
|
|
431,715
|
Earnings (loss) before
the following:
|
|
$
34,213
|
|
$
4,725
|
|
$
46,307
|
|
$
(7,577)
|
Restructuring and other
related costs
|
|
819
|
|
5,694
|
|
23,729
|
|
30,083
|
Other expense
(income)
|
|
885
|
|
5,547
|
|
14,352
|
|
14,356
|
Impairment of
goodwill
|
|
—
|
|
—
|
|
—
|
|
190,911
|
Earnings (loss) before
interest and income taxes
|
|
$
32,509
|
|
$
(6,516)
|
|
$
8,226
|
|
$ (242,927)
|
Interest expense and
other financing costs
|
|
41,227
|
|
23,045
|
|
150,851
|
|
56,041
|
(Loss) before income
taxes
|
|
$
(8,718)
|
|
$
(29,561)
|
|
$ (142,625)
|
|
$ (298,968)
|
Income tax expense
(recovery)
|
|
602
|
|
11,931
|
|
(17,649)
|
|
12,925
|
Net loss
|
|
$
(9,320)
|
|
$
(41,492)
|
|
$ (124,976)
|
|
$ (311,893)
|
(Loss) earnings per
share attributable to common
shareholders:
|
|
|
|
|
|
|
|
|
Basic (loss) earnings
per share
|
|
$
(0.08)
|
|
$
(0.34)
|
|
$
(1.03)
|
|
$
(2.52)
|
Diluted (loss)
earnings per share
|
|
$
(0.08)
|
|
$
(0.34)
|
|
$
(1.03)
|
|
$
(2.52)
|
Weighted average number
of shares (millions):
|
|
|
|
|
|
|
|
|
Basic
|
|
122.3
|
|
122.5
|
|
121.8
|
|
123.6
|
Diluted
|
|
122.3
|
|
122.5
|
|
121.8
|
|
123.6
|
Consolidated Statements of Other Comprehensive Income
(Loss)
(In thousands of
Canadian dollars)
|
Three months ended
December 31,
|
Twelve months
ended December 31,
|
|
2023
|
|
2022
|
|
2023
|
|
2022
|
|
|
(Unaudited)
|
|
(Unaudited)
|
|
(Audited)
|
|
(Audited)
|
Net loss
|
|
$
(9,320)
|
|
$
(41,492)
|
|
$ (124,976)
|
|
$ (311,893)
|
Other comprehensive
income (loss)
|
|
|
|
|
|
|
|
|
Actuarial (losses)
gains that will not be reclassified to profit
or loss (Net of tax of $6.6 million and $4.4 million;
2022: $0.0 million and $14.6
million)
|
|
$
(19,580)
|
|
$
17,910
|
|
$
12,313
|
|
$
40,095
|
Change in revaluation
surplus (Net of tax of $6.4 million and
$10.6 million; 2022: $0.0 million and $0.0 million)
|
|
$
22,782
|
|
$
—
|
|
$
40,815
|
|
$
—
|
Total items that will
not be reclassified to profit or loss
|
|
$
3,202
|
|
$
17,910
|
|
$
53,128
|
|
$
40,095
|
Items that are or may
be reclassified subsequently to profit
or
loss:
|
|
|
|
|
|
|
|
|
Change in fair value
of investments (Net of tax of $0.0 million and $0.0 million; 2022: $0.0 million and $0.0
million)
|
|
$
(5,504)
|
|
$
—
|
|
$
(5,504)
|
|
$
—
|
Change in accumulated
foreign currency translation adjustment (Net of tax of $0.0
million and $0.0 million; 2022: $0.0 million and $0.0
million)
|
|
(8,759)
|
|
(6,096)
|
|
(8,939)
|
|
28,972
|
Change in foreign
exchange on long-term debt designated as a net investment hedge
(Net of tax of $1.3 million and $1.2 million; 2022: $0.0 million
and $3.8 million)
|
|
7,194
|
|
6,313
|
|
6,592
|
|
(20,037)
|
Change in cash flow
hedges (Net of tax of $1.3 million and $3.9 million;
2022: $0.0 million and $6.3 million)
|
|
(2,091)
|
|
3,896
|
|
(8,469)
|
|
20,326
|
Total items that are or
may be reclassified subsequently to profit or loss
|
|
$
(9,160)
|
|
$
4,113
|
|
$
(16,320)
|
|
$
29,261
|
Total other
comprehensive income (loss)
|
|
$
(5,958)
|
|
$
22,023
|
|
$
36,808
|
|
$
69,356
|
Comprehensive (loss)
income
|
|
$
(15,278)
|
|
$
(19,469)
|
|
$
(88,168)
|
|
$ (242,537)
|
Consolidated Statements of Changes in Total Equity
|
|
|
|
Accumulated other
comprehensive income (loss)
|
|
|
(In thousands of
Canadian dollars)
|
Share
capital
|
Retained
earnings
|
Contributed
surplus
|
Foreign
currency
translation
adjustment(i)
|
Unrealized
gains and
losses on
cash flow
hedges(i)
|
Unrealized
gains on fair
value of
investments(i)
|
Revaluation
surplus(iii)
|
Treasury
stock
|
Total
equity
|
Balance at December
31, 2022(iii)
|
$
850,086
|
809,616
|
—
|
10,972
|
12,885
|
2,945
|
2,745
|
(25,916)
|
$
1,663,333
|
Net loss
|
—
|
(124,976)
|
—
|
—
|
—
|
—
|
—
|
—
|
(124,976)
|
Other
comprehensive income (loss)(ii)
|
—
|
12,313
|
—
|
(2,347)
|
(8,469)
|
(5,504)
|
40,815
|
—
|
36,808
|
Dividends declared
($0.84 per share)
|
10,178
|
(102,722)
|
—
|
—
|
—
|
—
|
—
|
—
|
(92,544)
|
Share-based
compensation expense
|
—
|
—
|
11,979
|
—
|
—
|
—
|
—
|
—
|
11,979
|
Deferred taxes on
share-based compensation
|
—
|
—
|
1,100
|
—
|
—
|
—
|
—
|
—
|
1,100
|
Exercise of stock
options
|
7,395
|
—
|
(1,363)
|
—
|
—
|
—
|
—
|
—
|
6,032
|
Shares
re-purchased
|
(4,498)
|
—
|
(11,595)
|
—
|
—
|
—
|
—
|
—
|
(16,093)
|
Sale of investment
property
|
—
|
6,213
|
—
|
—
|
—
|
—
|
(6,213)
|
—
|
—
|
Sale of treasury
stock
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
9,841
|
9,841
|
Settlement of
share-based compensation
|
1,305
|
(3,015)
|
(17,883)
|
—
|
—
|
—
|
—
|
8,892
|
(10,701)
|
Change in obligation
for repurchase of shares
|
9,011
|
—
|
20,989
|
—
|
—
|
—
|
—
|
—
|
30,000
|
Balance at December
31, 2023
|
$
873,477
|
597,429
|
3,227
|
8,625
|
4,416
|
(2,559)
|
37,347
|
(7,183)
|
$
1,514,779
|
|
|
|
|
|
|
Accumulated other
comprehensive income (loss)
|
|
|
(In thousands of
Canadian dollars)
|
Share
capital
|
Retained
earnings
|
Contributed
surplus
|
Foreign
currency
translation
adjustment
|
Unrealized
gains and
losses on
cash flow
hedges
|
Unrealized
gains on fair
value of
investments
|
Revaluation
surplus(iii)
|
Treasury
stock
|
Total
equity
|
Balance at January 1,
2022(iii)
|
$
847,016
|
1,212,244
|
5,371
|
2,037
|
(7,441)
|
2,945
|
$
2,745
|
(26,246)
|
$ 2,038,671
|
Net loss
|
—
|
(311,893)
|
—
|
—
|
—
|
—
|
—
|
—
|
(311,893)
|
Other
comprehensive income (loss)(ii)
|
—
|
40,095
|
—
|
8,935
|
20,326
|
—
|
—
|
—
|
69,356
|
Dividends declared
($0.80 per share)
|
—
|
(99,084)
|
—
|
—
|
—
|
—
|
—
|
—
|
(99,084)
|
Share-based
compensation expense
|
—
|
—
|
20,121
|
—
|
—
|
—
|
—
|
—
|
20,121
|
Modification of stock
compensation plan
|
—
|
—
|
(3,595)
|
—
|
—
|
—
|
—
|
—
|
(3,595)
|
Deferred taxes on
share-based compensation
|
—
|
—
|
(1,350)
|
—
|
—
|
—
|
—
|
—
|
(1,350)
|
Exercise of stock
options
|
7,433
|
—
|
(1,289)
|
—
|
—
|
—
|
—
|
—
|
6,144
|
Shares
re-purchased
|
(17,400)
|
(10,758)
|
(30,719)
|
—
|
—
|
—
|
—
|
—
|
(58,877)
|
Shares purchased by
RSU trust
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
(7,500)
|
(7,500)
|
Settlement of
share-based compensation
|
—
|
—
|
(15,560)
|
—
|
—
|
—
|
—
|
7,830
|
(7,730)
|
Change in obligation
for repurchase of shares
|
13,037
|
(20,988)
|
27,021
|
—
|
—
|
—
|
—
|
—
|
19,070
|
Balance at December 31,
2022
|
$
850,086
|
809,616
|
—
|
10,972
|
12,885
|
2,945
|
2,745
|
(25,916)
|
$ 1,663,333
|
(i)
|
Items that are or may
be subsequently reclassified to profit or loss.
|
(ii)
|
Included in other
comprehensive income (loss) is the change in actuarial gains and
losses that will not be reclassified to profit or loss and has been
reclassified to retained earnings.
|
(iii)
|
Restated, refer to
Note 4 of the Company's Audited Consolidated Financial
Statements.
|
Consolidated Statements of Cash Flows
(In thousands of
Canadian dollars)
|
Three months ended
December 31,
|
Twelve months
ended December 31,
|
2023
|
2022
|
2023
|
2022
|
CASH PROVIDED BY (USED
IN):
|
(Unaudited)
|
(Unaudited)
|
(Audited)
|
(Audited)
|
Operating
activities
|
|
|
|
|
|
|
|
|
Net
earnings
|
|
$
(9,320)
|
|
$ (41,492)
|
|
$
(124,976)
|
|
$
(311,893)
|
Add (deduct) items not
affecting cash:
|
|
|
|
|
|
|
|
|
Change in fair value
of biological assets
|
|
(8,852)
|
|
(26,996)
|
|
19,556
|
|
15,108
|
Depreciation and
amortization
|
|
67,394
|
|
61,905
|
|
271,394
|
|
233,937
|
Share-based
compensation
|
|
4,246
|
|
2,902
|
|
11,979
|
|
19,387
|
Deferred income tax
(recovery) expense
|
|
75,126
|
|
50,791
|
|
86,959
|
|
57,406
|
Current income tax
(recovery) expense
|
|
(74,524)
|
|
(38,860)
|
|
(104,608)
|
|
(44,481)
|
Interest expense and
other financing costs
|
|
41,227
|
|
23,045
|
|
150,851
|
|
56,041
|
(Gain) loss on sale of
long-term assets
|
|
(2,451)
|
|
280
|
|
(516)
|
|
1,966
|
Impairment of property
and equipment, ROU assets, and goodwill
|
|
15
|
|
3,353
|
|
9,011
|
|
212,363
|
Change in fair value
of non-designated
derivatives
|
|
2,160
|
|
14,451
|
|
(4,632)
|
|
(4,956)
|
Impairment of
investments
|
|
1,953
|
|
—
|
|
1,953
|
|
—
|
Change in net pension
obligation
|
|
168
|
|
1,826
|
|
2,400
|
|
8,764
|
Net income taxes
refunded (paid)
|
|
42,039
|
|
(304)
|
|
39,028
|
|
(30,162)
|
Interest paid, net of
capitalized interest
|
|
(41,614)
|
|
(20,483)
|
|
(150,425)
|
|
(54,897)
|
Change in provision
for restructuring and other
related costs
|
|
(4,590)
|
|
(653)
|
|
(33,542)
|
|
995
|
Change in derivatives
margin
|
|
(2,425)
|
|
4,710
|
|
(6,409)
|
|
2,012
|
Cash settlement of
derivatives
|
|
(2,036)
|
|
(3,931)
|
|
3,361
|
|
(3,931)
|
Other
|
|
275
|
|
9,958
|
|
(5,617)
|
|
(403)
|
Change in non-cash
operating working capital
|
|
(5,779)
|
|
1,818
|
|
11,116
|
|
(107,938)
|
Cash provided by
operating activities
|
|
$
83,012
|
|
$
42,320
|
|
$
176,883
|
|
$
49,318
|
Investing
activities
|
|
|
|
|
|
|
|
|
Additions to long-term
assets
|
|
$
(41,786)
|
|
$ (97,950)
|
|
$
(198,181)
|
|
$
(355,734)
|
Interest paid and
capitalized
|
|
(485)
|
|
(5,578)
|
|
(2,969)
|
|
(22,217)
|
Proceeds from sale of
long-term assets
|
|
7,515
|
|
484
|
|
18,039
|
|
607
|
Purchase of
investments
|
|
—
|
|
(600)
|
|
(200)
|
|
(600)
|
(Payments of) Proceeds
from legal settlement
|
|
(5,256)
|
|
929
|
|
(5,256)
|
|
929
|
Cash used in investing
activities
|
|
$
(40,012)
|
|
$
(102,715)
|
|
$
(188,567)
|
|
$
(377,015)
|
Financing
activities
|
|
|
|
|
|
|
|
|
Dividends
paid
|
|
$
(20,632)
|
|
$ (24,551)
|
|
$
(92,544)
|
|
$ (99,084)
|
Net (decrease) in
long-term debt
|
|
(15,937)
|
|
106,571
|
|
253,064
|
|
447,045
|
Payment of lease
obligation
|
|
(8,223)
|
|
(6,943)
|
|
(32,951)
|
|
(33,892)
|
Receipt of lease
inducement
|
|
—
|
|
1
|
|
—
|
|
6,848
|
Exercise of stock
options
|
|
603
|
|
1,545
|
|
6,032
|
|
6,144
|
Repurchase of
shares
|
|
—
|
|
(31,313)
|
|
(16,093)
|
|
(58,877)
|
Payment of financing
fees
|
|
(46)
|
|
(38)
|
|
(3,378)
|
|
(3,942)
|
Sale (purchase) of
treasury shares
|
|
—
|
|
—
|
|
9,841
|
|
(7,500)
|
Cash (used in) provided
by financing activities
|
|
$
(44,235)
|
|
$
45,272
|
|
$
123,971
|
|
$ 256,742
|
(Decrease) increase
in cash and cash equivalents
|
|
(1,235)
|
|
(15,123)
|
|
112,287
|
|
(70,955)
|
Cash and cash
equivalents, beginning of period
|
|
204,598
|
|
106,199
|
|
91,076
|
|
162,031
|
Cash and cash
equivalents, end of period
|
|
$
203,363
|
|
$
91,076
|
|
$
203,363
|
|
$
91,076
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/maple-leaf-foods-reports-fourth-quarter-and-full-year-2023-financial-results-302068414.html
SOURCE Maple Leaf Foods Inc.